Objective: To explore the survival status and affecting factors among patients diagnosed as AIDS, in Henan province. Methods: Database of AIDS patients were downloaded from the China information system for disease prevention and control-AIDS with a retrospective study conducted. Inclusion criteria on patients would involve those diagnosed between 2008 and 2015, aged 15 years or above. Results: A total number of 25 525 HIV/AIDS patients were enrolled in this study. During the follow-up period, the overall mortality among all the patients was 24.9%. Mortality of those having received the highly active antiretroviral treatment (HAART) was 14.4%. Proportion for the treatment coverage increased gradually, from 72.1% in 2008 to 92.8% in 2015. The overall mortality rate dropped from 21.2% to 4.1% and the mortality of those having received HAART patients dropped from 9.2% to 2.6%. Results from the multiple factors analysis showed that factors as: CD(4)(+) T cell count (CD(4)) <50 cell/μl when the AIDS diagnosis was made (adjusted HR=2.45) were related to higher risk on mortality among HIV/AIDS patients. Patients having received HAART (adjusted HR=0.13) had lower risks on mortality. Among patients having received treatment, results from the multiple factors analysis showed that factor as TMP-SMZ dosage being administered (adjusted HR=0.76) were related to low mortality risk. As for CD(4) counts of the patients, the adjusted HRs were 1.26 in 50-cells/μl group and 1.97 in the <50 cells/μl group, respectively when the diagnosis was made. Both groups had high risk on mortality patients with lower baseline CD(4) counts (adjusted HR were 1.44, 1.84 in 50-cells/μl and <50 cells/μl groups, respectively) seemed to have higher risk on mortality. Conclusions: Antiretroviral therapy appeared an important factor that affecting the survival of HIV/AIDS patients. CD(4) count test, early identifying and treating the AIDS patients together with providing TMP-SMZ prevention and treatment programs, were important approaches in extending the survival time so as to reduce the death rates from AIDS related illnesses.
目的：了解河南省HIV感染者/AIDS患者（HIV/AIDS ）确诊AIDS后生存状况及其影响因素。 方法：从国家艾滋病综合防治信息系统下载河南省相关数据库，筛选出2008-2015年间确诊为AIDS且≥15岁患者，进行回顾性研究。 结果：纳入25 525例研究对象，观察期内病死率为24.9%，其中接受高效抗反转录病毒治疗（HAART）为14.4%。治疗比例从2008年的72.1%上升到2015年的92.8%，同期病死率从21.2%下降到4.1%，其中接受HAART者从9.2%下降到2.6%。多因素分析显示，确诊AIDS时CD(4)(＋)T淋巴细胞（CD(4)）计数<50个/μl的患者死亡风险大（aHR ＝ 2.45）；接受HAART的患者死亡风险低（aHR＝0.13）。在接受HAART患者中，有复方磺胺甲恶唑（TMP-SMZ）服用史的患者死亡风险低（aHR＝0.76）；确诊AIDS时CD(4)计数50～个/μl组和<50个/μl组死亡风险高（aHR值分别为1.26和1.97）；基线CD(4)计数50～个/μl、<50个/μl组死亡风险高（aHR值分别为1.44和1.84）。 结论：抗病毒治疗是影响HIV/AIDS生存时间的重要因素，加强HIV/AIDS的CD(4)检测，尽早纳入HAART，同时及时开展TMP-SMZ预防治疗，是减少患者AIDS相关疾病死亡的有效途径。.
Keywords: HIV/AIDS; Retrospective cohort; Survival status.